BioSyent Inc. (CVE:RX – Free Report) – Investment analysts at Bloom Burton upped their FY2025 EPS estimates for BioSyent in a research report issued on Monday, March 17th. Bloom Burton analyst D. Martin now forecasts that the company will post earnings of $0.81 per share for the year, up from their prior estimate of $0.80. The consensus estimate for BioSyent’s current full-year earnings is $0.69 per share. Bloom Burton also issued estimates for BioSyent’s FY2027 earnings at $0.94 EPS.
BioSyent Stock Performance
CVE:RX opened at C$11.25 on Tuesday. The firm has a 50 day simple moving average of C$11.04 and a 200-day simple moving average of C$11.11. The company has a debt-to-equity ratio of 2.90, a current ratio of 3.92 and a quick ratio of 6.91. The firm has a market cap of C$128.67 million, a PE ratio of 18.26 and a beta of 0.93. BioSyent has a 1-year low of C$8.24 and a 1-year high of C$12.13.
Insider Activity
About BioSyent
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Further Reading
- Five stocks we like better than BioSyent
- 3 Best Fintech Stocks for a Portfolio Boost
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- How to find penny stocks to invest and trade
- 3 Must-Own Stocks to Build Wealth This Decade
- What is a Bond Market Holiday? How to Invest and Trade
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.